Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsPeter L. Collins, Thomas Charles McCarty
Life of this patent
Estimating the term…
Abstract
Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
Claims17
A recombinant respiratory syncytial virus (RSV) attenuated by one or more modifications to a RSV genome, wherein the one or more modifications comprise:
- a NS1 gene and a NS2 gene shifted from gene positions 1 and 2 to gene positions 7 and 8 of the RSV genome, respectively.
Dependencies are inferred from the claim text.